Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer.
Vanita Noronha, Kumar Prabhash(Homi Bhabha National Institute), Tejpal Gupta(Tata Memorial Hospital), Aparna Manjrekar, Vijay Patil, Sarbani Ghosh Laskar(Tata Memorial Hospital), Vijayalakshmi Mathrudev, Vedang Murthy(Homi Bhabha National Institute), Pankaj Chaturvedi(Tata Memorial Hospital), Kamesh Maske, Amit Joshi(Dr. Rajendra Prasad Government Medical College), Devendra Chaukar(Tata Memorial Hospital), Nikhil Pande, Ashwini Budrukkar(Tata Memorial Hospital), Vikas Talreja, Jaiprakash Agarwal(Tata Memorial Hospital), Anil D′Cruz(Apollo Hospitals), Prathamesh Pai(Tata Memorial Hospital), Dilip Vallathol(Tata Memorial Hospital), Arun Chandrasekharan
Cited by 26
Related Papers
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
|European Urology|2017|644
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
|European Urology|2020|396
Preferred reporting of case series in surgery; the PROCESS guidelines
|International Journal of Surgery|2016|384
Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis
|European Journal of Nuclear Medicine and Molecular Imaging|2011|377